子宫颈癌组织中缺氧诱导因子1α蛋白的表达及其与血管生成的关系

缺氧诱导因子(hypoxia—inducible factor，HIF)1是在缺氧条件下广泛存在于哺乳动物和人体内的一种转录因子，主要由两个亚单位HIF-1α和HIF-1β组成。近年来的研究表明，HIF-1α与肿瘤的发生、发展密切相关，而在正常组织则无表达。HIF—1α在肿瘤生长、血管形成中起重要作用。本研究检测宫颈癌组织中HIF-1α的表达，并分析其与微血管密度(MVD)的关系，旨在探讨HIF-1α在宫颈癌组织中的表达及其与血管生成的关系。     

PTEN基因对卵巢癌耐药细胞系C13K顺铂耐药性的影响

目的:探讨第10号染色体上PTEN对人卵巢癌顺铂耐药细胞株C13K顺铂耐药性的逆转作用。方法:将野生型PTEN基因真核表达质粒在脂质体介导下转染人卵巢癌耐药细胞系C13K细胞,同时以转染空载体和未转染C13K细胞作为对照,分别应用逆转录聚合酶链式反应(RT-PCR)及蛋白印迹法(W estern blot)检测PTEN mRNA及蛋白表达水平,对转染细胞株进行四甲基偶氮噻唑蓝(MTT)实验,观察PTEN基因对肿瘤细胞生长的抑制作用和C13K细胞对顺铂药物敏感性的影响,流式细胞仪(FACS)分析细胞的凋亡。结果:转染48 h后,与对照组相比,转染野生型PTEN基因能明显增加C13K细胞PTEN mRNA和蛋白的表达,差异有统计学意义(P<0.05);MTT法显示,转染野生型PTEN基因的C13K细胞生长明显慢于转染空载体和未转染的C13K细胞,转染PTEN的C13K细胞对顺铂的敏感性显著增加;FACS分析显示,顺铂作用24h后,转染PTEN基因能够显著提高C13K细胞凋亡率。结论:转染野生型PTEN质粒能有效地提高C13K细胞内PTEN的表达,恢复细胞对顺铂的敏感性。     

宫颈癌基因治疗

影响宫颈癌疗效的重要因素是早期转移和术后复发.基因治疗与手术、放疗、化疗等常规疗法相比,在控制宫颈癌细胞的增殖,预防和延缓癌症复发、转移,以及提高宫颈癌患者生活质量等方面具有独特优势.现综述近几年宫颈癌基因治疗研究进展.     

宫颈癌组织中环氧合酶-2表达及其与血管生成和细胞增殖的关系

目的　探讨宫颈癌组织中环氧合酶 2 (COX 2 )表达及其与血管生成和细胞增殖的关系。方法　采用免疫组织化学S P法检测 41例宫颈癌和 10例正常宫颈上皮组织中COX 2表达 ,并检测其微血管密度 (CD3 4标记 )和癌细胞增殖指数 (Ki 67标记 )。结果　宫颈癌组织中COX 2、微血管密度、Ki 67指数明显高于正常宫颈上皮组织 (P <0 .0 1) ,COX 2高表达与宫颈癌淋巴结转移和浸润深度有关 (P <0 .0 5 ) ,与患者年龄、临床分期、组织学类型、分化程度无关 (P >0 .0 5 ) ,COX 2表达阳性者微血管密度和Ki 67指数明显高于COX 2表达阴性者 (P <0 .0 5 )。结论　COX 2过度表达可能参与宫颈癌的发生发展 ,且与宫颈癌新生血管的形成和细胞增殖有密切关系 ,可作为反映宫颈癌生物学行为的有效指标     

外源性子宫珠蛋白基因对宫颈癌HeLa细胞增殖及凋亡的影响

目的探讨人子宫珠蛋白（UG）基因对宫颈癌Hela细胞系细胞增殖及凋亡的影响。方法构建真核细胞表达载体pcDNA3．1-UG（＋），以脂质体介导法稳定转染体外培养的人宫颈癌Hela细胞，同时转染空载体pcDNA3．1质粒，以未转染细胞为对照，转染成功后分别命名为pcDNA3．1-UG（＋）／Hela组、pcDNA3．1／Hela组、Hela组。应用逆转录聚合酶链式反应（RT-PCR）、Western blot方法分析目的基因表达，并采用四甲基偶氮唑蓝（MTT）法和流式细胞术检测细胞增殖和细胞凋亡。结果pcDNA3，1-UG（＋）／Hela组UGmRNA及UG蛋白出现明显的高表达，与对照组细胞相比差异有统计学意义（P〈0．05）；pcDNA3．1UG（＋）／Hela组细胞生长速度明显慢于未转染Hela细胞，其细胞凋亡率与未转染Hela细胞相比差异也有统计学意义；然而pcDNA3．1／Hela组细胞生长速度和凋亡率均无明显变化。结论转染UG基因能诱导Hela细胞凋亡及抑制Hela细胞生长。     

PTEN基因增强卵巢癌A2780细胞对紫杉醇敏感性的研究

背景与目的:近来的研究表明PTEN基因(phosphatase and tensin homology deleted on chromosome ten,第10号染色体上磷酸酶和张力蛋白同源缺失的基因)失活在肿瘤化疗耐药发挥了重要作用。本文研究外源性PTEN基因稳定转染人卵巢癌A2780细胞后对紫杉醇敏感性的影响。方法:将野生型PTEN基因真核表达质粒在脂质体介导下转染人卵巢癌A2780细胞,同时以转染空载体和未转染细胞作为对照(3组细胞分别命名为WT-PTEN/A2780,GFP/A2780和A2780),分别应用RT-PCR和蛋白印迹技术检测各组细胞PTEN mRNA转录和蛋白表达的变化;四甲基偶氮唑蓝实验观察转染PTEN基因对肿瘤细胞生长的抑制作用和A2780细胞对紫杉醇药物敏感性的影响,流式细胞仪(FACS)分析细胞凋亡情况。结果:与对照组相比,转染野生型PTEN基因能明显增加A2780细胞PTENmRNA转录和蛋白的表达,差异有显著性(P<0.05);MTT法显示,WT-PTEN/A2780细胞生长明显慢于GFP/A2780和A2780细胞;紫杉醇对WT-PTEN/A2780,GFP/A2780和A2780的IC50值分别为(7.6±0.40)nmol/l、(22.5±0.9)nmol/l和(22.7±0.8)nmol/l,WT-PTEN/A2780细胞对紫杉醇药物敏感性显著增加(P<0.05);FACS分析显示,紫杉醇作用24h后,WT-PTEN/A2780,GFP/A2780和A2780的凋亡率分别为(34.6±1.6)%、(13.5±0.9)%和(12.7±1.0)%,差异有显著性(P<0.05)。结论:转染野生型PTEN重组质粒能有效提高A2780细胞内PTEN的表达,诱导A2780细胞凋亡,显著增加A2780细胞对紫杉醇杀伤的敏感性。     

沉默轴突导向蛋白4D基因对卵巢癌SKOV3细胞恶性生物学行为的影响

Objective To observe the effect of DNA Sema4D gene silencing by RNA interfering on the proliferation, migration and invasion of human ovarian cancer SKOV3 cells, and to study the effect of pshRNASema4D on the growth of SKOV3 cells in transplanted tumor in nude nice. Methods Recombinant plasmid pshRNASema4D-A, B and C were respectively transfected into SKOV3 cells by lipofetamine 2000, while cells transfected by plasmid vector pcDNA3.1 and cells untreated as control groups. RT-PCR was adopted to select the recombinant plasmid which showed the most optimal inhibition effect. RT-PCR and Western blotwere used to detected the mRNA and protein expression of Sema4D in SKOV3 cells tranfected for 24, 48 and 72 hours. MTT assay was used to investigate the proliferation of the SKOV3 cells after trasnsfection. Transwell cell migration and invasion assays were used to investigate the migration and invasion abilities of the SK0V3 cells after trasnsfection. Human ovarian cancer model was established in nude mice, and the nude mice were treated with pshRNASema4D-B once every 3 days for 3 weeks. The bulk of the transplanted tumor was measured. Results Three Sema4D-targeted short hairpin RNA (shRNA) A, B and C were successfully inserted into the plasmid vector pshRNA, and the coding sequences of the obtained shRNA were consistent with the designed fragment. The results indicated that both recombinant plasmid pshRNASema4D-A and B could effectively knock down the expression of Sema4D gene in human ovarian cancer cells, of which pshRNASema4D-B was the better choice, while no effect of pshRNASema4D-C was seen. RT-PCR results showed that the relative mRNA expression of Sema4D gene in SKOV3 cells transfected with pshRNA-Sema4D for 24, 48 and 72 hours were 0. 401 ±0.051, 0. 120 ±0.035 and 0.014 ±0. 015, respectively, which were significantly lower than that in SKOV3 cells transfected by empty vector and non-transfected cells at 72 hours after transfection. (0.521 ±0.019, 0.536 ±0.040,respectively, P<0.05). The Westen blot analysis manifested that the relative expression of Sema4D protein of SKOV3 cells transfected by pshRNASema4D for 24, 48 and 72 hours were 0. 196 ± 0. 023, 0. 074 ± 0. 015 and 0. 040 ± 0.014, respectively, which were significantly lower than that in SKOV3 cells transfected by empty vector and non-transfected cells at 72 hours after transfection. (0. 275 ± 0. 009, 0. 282 ± 0. 015, respectively, P < 0. 05 ). Comparing with the empty vector-transfected and non-transfected cells, the proliferation, invasion and migration ability of SKOV3 cells transfected with pshRNA-Sema4D were obviously weakened. The pshRNASema4D-B significantly suppressed the growth of the SKOV3 cells-transplanted tumors in nude mice, and the IR( inhibitory rate ) of pshRNASema4D-B group was ( 61.0 ± 3.3 ) % ( P < 0.05). Conclusions Sema4D can be successfully silenced by RNA interfering in human ovarian cancer SKOV3 cells. Downregulation of Sema4D can inhibit the proliferation, migration and invasion of ovarian cancer cells. The pshRNASema4D can significantly suppress the growth in transplanted tumor of human ovary cancer in nude mice. Sema4D may become a candidate gene of gene therapy of human ovarian cancer.     

分子靶向治疗在妇科恶性肿瘤中的研究进展

分子靶向治疗（molecular targeted therapy,MTT）作为肿瘤治疗的新手段,通过特异性靶向肿瘤发生发展中起关键作用的分子或相关细胞的信号转导通路控制细胞基因表达,从而抑制或杀死癌细胞,基于对细胞分子生物学及信号转导机制,在分子水平上对肿瘤细胞进行直接或间接的精确打击。肿瘤分子靶向治疗因其具有疗效高、不良反应低的特点而备受瞩目,其出现为肿瘤的治疗开辟了新的领域和广阔的前景。本文就妇科恶性肿瘤中分子靶向治疗的研究进展进行综述。      

宫颈癌基因治疗

影响宫颈癌疗效的重要因素是早期转移和术后复发。基因治疗与手术、放疗、化疗等常规疗法相比，在控制宫颈癌细胞的增殖，预防和延缓癌症复发、转移，以及提高宫颈癌患者生活质量等方面具有独特优势。现综述近几年宫颈癌基因治疗研究进展。     

PTEN基因转染对卵巢癌A2780细胞周期和增殖能力影响的研究

目的:研究外源性PTEN基因稳定转染对人卵巢癌A2780细胞周期和增殖能力的影响。方法:构建PTEN基因的野生型真核表达质粒pEGFP-C1-WT-PTEN和突变型表达质粒pEG-FP-C1-C124A-PTEN,以脂质体介导法转染体外培养的人卵巢癌细胞株A2780,同时转染空载体pEGFP-C1质粒,以未转染细胞为对照(转染成功后分别命名为WT-PTEN/A2780组、C124A-PTEN/A2780组、pEGFP-C1/A2-780组和A2780组。应用RT-PCR、Western blot方法分析目的基因及其蛋白表达,并采用MTT法和流式细胞术检测细胞增殖和细胞周期。结果:与对照细胞相比,WT-PTEN/A2780组和C124A-PTEN/A2780组PTEN mRNA及PTEN蛋白出现明显的高表达,与对照组细胞相比差异有统计学意义(t=5.300,P=0.034;t=11.963,P=0.007;t=7.869,P=0.016;t=22.421,P=0.002);WT-PTEN/A2780组细胞生长速度明显慢于未转染A2780细胞,然而C124A-PTEN/A2780组和pEGFP-C1/A2780组细胞生长速度无明显变化。流式细胞术显示WT-PTEN/A2780细胞G1期细胞数增加到(71.18±4.34)%,S期细胞数变为(17.48±1.96)%,与对照组相比差异有统计学意义(t=19.508,P=0.003;t=25.354,P=0.002),提示从G1期到S期发生抑制。结论:野生型PTEN可依赖其磷酸酶活性使A2780细胞在G1/S期发生细胞周期阻滞,并抑制A2780细胞增殖。